21 April 2010
- Dr. Murray, an industry-experienced psychiatrist, to lead Company’s CNS-focused development programs -
Martinsried, Germany — Affectis Pharmaceuticals AG today announced that Dr. Stephen Murray has been appointed as Chief Medical Officer (CMO).
| File | File size |
|---|---|
 21 Apr 2010 - Stephen Murray CMO - engl | 21 Kb |
22 March 2010
Martinsried, Germany—Affectis Pharmaceuticals AG today announced it has raised €3.3M in the first tranche of a Series D financing. Existing investors LSP, Aescap Venture, KfW, Bayernkapital and EMBL Ventures were participating in the round. Moreover, the company announced.the appointment of Alex Martin as Chief Executive Officer. Mr. Martin had previously served on the Supervisory Board of Affectis and joined the company fulltime as CFO in August of 2009. He succeeds founding CEO Herbert Stadler, who is retiring.
| File | File size |
|---|---|
| Affectis Financing Round & Alex-Martin Mar 22 2010 | 21 Kb |
03 August 2009
Martinsried, Germany - Affectis Pharmaceuticals, a biopharmaceutical company developing novel drugs for the treatment of psychiatric and inflammatory disorders, today announced the appointment of Alex Martin as Chief Financial Officer. Mr. Martin brings over 20 years experience in the life sciences industry, most recently serving as Chief Operating Officer of Intercept Pharmaceuticals.
Herbert Stadler, founder and CEO of Affectis, commented, "We are please to have Alex join our team as he brings experience as both a CFO and an operating manager which will be invaluable as we continue to advance our pipeline and invest in our programs further."
| File | File size |
|---|---|
| Affectis - Alex Martin CFO Aug 3 2009 | 25 Kb |
Copyright © 2010 Affectis Pharmaceuticals AG. All Rights Reserved.
